{"log_id": 2107804804367207820, "direction": 0, "words_result_num": 43, "words_result": [{"probability": {"variance": 0.004378, "average": 0.979504, "min": 0.67753}, "location": {"width": 829, "top": 254, "height": 25, "left": 165}, "words": "MWS发现,结合型雌激素(CEE)或雌二醇(E2)在序贯联合或持续联合任何一种孕激素后均使患"}, {"probability": {"variance": 1e-05, "average": 0.998079, "min": 0.986212}, "location": {"width": 505, "top": 280, "height": 28, "left": 165}, "words": "者的乳腺癌相对风险度变大,且不同给药途径间未见差异"}, {"probability": {"variance": 0.001539, "average": 0.988981, "min": 0.806384}, "location": {"width": 835, "top": 308, "height": 26, "left": 165}, "words": "WHI研究中,乳腺癌的发生与所使用的连续联合使用结合型雌激素和醋酸甲羟孕酮(CEE+MPA)"}, {"probability": {"variance": 1e-06, "average": 0.999171, "min": 0.995897}, "location": {"width": 668, "top": 333, "height": 29, "left": 163}, "words": "相关,与安慰剂组相比,这些乳腺癌体积稍有增大且更常有局部淋巴结转移"}, {"probability": {"variance": 0.002451, "average": 0.990795, "min": 0.675214}, "location": {"width": 830, "top": 361, "height": 27, "left": 163}, "words": "HRT,特别是雌激素-孕激素联合治疗,会增加乳房X线检查的影像密度而可能不利于乳腺癌"}, {"probability": {"variance": 1e-06, "average": 0.998874, "min": 0.997219}, "location": {"width": 122, "top": 391, "height": 23, "left": 164}, "words": "的放射性检测"}, {"probability": {"variance": 6.3e-05, "average": 0.996017, "min": 0.978238}, "location": {"width": 123, "top": 441, "height": 23, "left": 163}, "words": "静脉血栓栓塞"}, {"probability": {"variance": 9.3e-05, "average": 0.996235, "min": 0.949519}, "location": {"width": 828, "top": 462, "height": 28, "left": 166}, "words": "HRT疗法与发生静脉血栓栓塞(VTE,即深静脉血栓或肺栓塞)的相对危险度升高有关。一项随"}, {"probability": {"variance": 9.6e-05, "average": 0.996051, "min": 0.948471}, "location": {"width": 829, "top": 491, "height": 27, "left": 163}, "words": "机对照试验和多个流行病学研究发现,HRT疗法使用者的VTE风险比不使用者高2-3倍。预计"}, {"probability": {"variance": 0.000445, "average": 0.99234, "min": 0.886473}, "location": {"width": 830, "top": 517, "height": 28, "left": 163}, "words": "不使用HRT疗法者5年内的VTE病例数,在50-59岁女性中约为3例1,000人,60-69岁女性中约为"}, {"probability": {"variance": 0.003241, "average": 0.97907, "min": 0.705761}, "location": {"width": 820, "top": 541, "height": 28, "left": 171}, "words": "例/1,000人。预计健康女性使用HRT疗法5年里新增VTE病例数为:50-59岁女性中为2-6例(最"}, {"probability": {"variance": 0.001608, "average": 0.980601, "min": 0.810817}, "location": {"width": 828, "top": 572, "height": 23, "left": 164}, "words": "佳估计值=4)/1,000人,60-69岁女性中为5-15例(最佳估计值=9)/1,000人。HRT疗法第一年"}, {"probability": {"variance": 0.018842, "average": 0.934627, "min": 0.569958}, "location": {"width": 196, "top": 598, "height": 24, "left": 165}, "words": "里较以后更易发生VTE"}, {"probability": {"variance": 0.000152, "average": 0.995016, "min": 0.933367}, "location": {"width": 733, "top": 622, "height": 26, "left": 203}, "words": "通常公认的VTE危险因子包括个人史或家族史,重度肥胖(体重指数,Body"}, {"probability": {"variance": 0.001131, "average": 0.991532, "min": 0.773699}, "location": {"width": 787, "top": 649, "height": 25, "left": 207}, "words": "ndex>30kg/m2)和系统性红斑狼疮(SLE)。静脉曲张在VTE中是否起作用尚无一致看"}, {"probability": {"variance": 0, "average": 0.999814, "min": 0.999814}, "location": {"width": 22, "top": 680, "height": 20, "left": 202}, "words": "法"}, {"probability": {"variance": 0.001044, "average": 0.990544, "min": 0.789991}, "location": {"width": 789, "top": 701, "height": 26, "left": 203}, "words": "有VTE史或已知血栓形成倾向者发生VTE的风险升高。HRT疗法可能增加此风险。如有个"}, {"probability": {"variance": 1.6e-05, "average": 0.998228, "min": 0.980632}, "location": {"width": 791, "top": 729, "height": 25, "left": 205}, "words": "人或密集的血栓栓塞家族史或复发性自然流产应给予调查以排除血栓形成倾向体质。HRT"}, {"probability": {"variance": 4e-06, "average": 0.998938, "min": 0.987907}, "location": {"width": 791, "top": 754, "height": 25, "left": 202}, "words": "疗法在这些病人中应被视为禁忌,除非已经彻底评估了血栓形成倾向的危险因子或已开始"}, {"probability": {"variance": 0.007619, "average": 0.978168, "min": 0.510732}, "location": {"width": 710, "top": 781, "height": 24, "left": 203}, "words": "抗凝治疗。对那些早已开始抗凝治疗的女性需仔细考虑使用HRT疗法的受益-风险"}, {"probability": {"variance": 0.000668, "average": 0.994307, "min": 0.833673}, "location": {"width": 783, "top": 807, "height": 25, "left": 211}, "words": "长时间静止不动、重伤或大手术可能会使VTE的风险暂时升高。对所有术后病人均应谨慎"}, {"probability": {"variance": 0.000354, "average": 0.994411, "min": 0.911332}, "location": {"width": 787, "top": 833, "height": 25, "left": 206}, "words": "考虑VTE的预防措施以防手术后发生VTE。当选择性手术后可能需长时间静止不动时,尤"}, {"probability": {"variance": 0.001015, "average": 0.993337, "min": 0.797234}, "location": {"width": 789, "top": 859, "height": 25, "left": 204}, "words": "其是腹部或下肢骨科手术,如有可能应考虑在术前4-6周暂时停止HRT治疗。只有当女性"}, {"probability": {"variance": 7e-06, "average": 0.998856, "min": 0.988193}, "location": {"width": 364, "top": 887, "height": 22, "left": 203}, "words": "完全能自主活动后才应重新开始HRT治疗"}, {"probability": {"variance": 1.7e-05, "average": 0.998269, "min": 0.979942}, "location": {"width": 792, "top": 912, "height": 26, "left": 201}, "words": "如使用HRT疗法后出现静脉血栓栓塞则应停药。应告之患者,若意识到可能为血栓栓塞的"}, {"probability": {"variance": 2e-06, "average": 0.99919, "min": 0.993763}, "location": {"width": 648, "top": 939, "height": 26, "left": 203}, "words": "症状(如单腿疼痛性水肿,胸部突发疼痛,呼吸困难),须立即联系医生"}, {"probability": {"variance": 0.000241, "average": 0.99095, "min": 0.955868}, "location": {"width": 113, "top": 992, "height": 22, "left": 164}, "words": "冠心病(CHD"}, {"probability": {"variance": 1.9e-05, "average": 0.998197, "min": 0.979317}, "location": {"width": 830, "top": 1014, "height": 27, "left": 163}, "words": "随机对照试验未发现连续联合使用结合型雌激素和MPA对心血管的益处。2项大规模临床试验"}, {"probability": {"variance": 0.002909, "average": 0.982192, "min": 0.701531}, "location": {"width": 823, "top": 1038, "height": 27, "left": 170}, "words": "WHI和HERS,即心脏和雌激素/孕激素替代研究)显示在HRT疗法使用第一年里,心血管病发"}, {"probability": {"variance": 1.4e-05, "average": 0.998383, "min": 0.981375}, "location": {"width": 829, "top": 1066, "height": 26, "left": 163}, "words": "病率可能增加且没有总体益处。其它HRT产品在心血管病发病率或死亡率方面的随机对照试验"}, {"probability": {"variance": 4e-06, "average": 0.998775, "min": 0.990858}, "location": {"width": 586, "top": 1093, "height": 27, "left": 163}, "words": "资料有限,因此尚不肯定上述结果是否也同样适用于其它HRT产品"}, {"probability": {"variance": 7e-06, "average": 0.996101, "min": 0.993436}, "location": {"width": 38, "top": 1144, "height": 23, "left": 165}, "words": "卒中"}, {"probability": {"variance": 0.000672, "average": 0.992808, "min": 0.833434}, "location": {"width": 808, "top": 1169, "height": 25, "left": 185}, "words": "项大规模随机临床试验(WHI-试验)发现,作为次要结果,健康女性连续联合使用结合型雌激"}, {"probability": {"variance": 2.4e-05, "average": 0.997919, "min": 0.969655}, "location": {"width": 829, "top": 1196, "height": 24, "left": 164}, "words": "素和MPA治疗期间,缺血性卒中的风险增加。预计非HRT使用者5年内,50-59岁女性的卒中病"}, {"probability": {"variance": 0.011627, "average": 0.968164, "min": 0.456934}, "location": {"width": 830, "top": 1222, "height": 24, "left": 163}, "words": "例数约为3例/1,000人,60-69岁女性约为11例/1,000人。预计使用结合型雌激素和MPA5年的女"}, {"probability": {"variance": 0.007854, "average": 0.980846, "min": 0.360364}, "location": {"width": 829, "top": 1247, "height": 26, "left": 165}, "words": "性,50-59岁使用者中新增病例数0-3例(最佳估计=1)1,000人,60-69岁使用者中新增病例数"}, {"probability": {"variance": 0.000431, "average": 0.990766, "min": 0.894314}, "location": {"width": 689, "top": 1275, "height": 25, "left": 163}, "words": "19例(最佳估计=4)1,000人。尚不明确上述结果是否也适用于其它HRT产品"}, {"probability": {"variance": 0, "average": 0.999945, "min": 0.999912}, "location": {"width": 62, "top": 1326, "height": 24, "left": 163}, "words": "卵巢癌"}, {"probability": {"variance": 0.000851, "average": 0.991342, "min": 0.849804}, "location": {"width": 810, "top": 1349, "height": 28, "left": 184}, "words": "些流行病学研究发现,子宫切除女性长期(至少5-10年)单一使用雌激素类HRT产品后,患卵"}, {"probability": {"variance": 2e-06, "average": 0.998964, "min": 0.99535}, "location": {"width": 830, "top": 1375, "height": 27, "left": 164}, "words": "巢癌的风险增加。尚不明确是否长期使用联合HRT疗法时卵巢癌的风险不同于单一使用雌激素"}, {"probability": {"variance": 0, "average": 0.999765, "min": 0.999488}, "location": {"width": 61, "top": 1405, "height": 23, "left": 164}, "words": "类产品"}, {"probability": {"variance": 6.5e-05, "average": 0.993291, "min": 0.979937}, "location": {"width": 83, "top": 1454, "height": 23, "left": 164}, "words": "其它疾病"}, {"probability": {"variance": 0.000123, "average": 0.996946, "min": 0.930269}, "location": {"width": 828, "top": 1478, "height": 26, "left": 165}, "words": "■雌激素可能导致体液潴留,因此应仔细观察心功能或肾功能不全患者。应密切观察终末期"}], "language": 3}